FDA GLP-1 Warning Letters Explained: What They Mean for Your Provider

You see a headline: “FDA sends warning letters to 30 GLP-1 telehealth companies.” Your provider may be on the list. Your next question — entirely reasonable — is whether your medication is still going to arrive.

The answer depends on what the warning letter actually says. A letter about misleading marketing copy is not the same as a letter about sterility violations. Neither is a shutdown order. But both are real regulatory signals that affect whether a provider can continue operating long-term.

This article explains how FDA warning letters work, what violations drove the two major GLP-1 warning waves, and how to interpret what you find in our warning letter tracker.

What an FDA warning letter is

An FDA warning letter is a formal written notice that a company — a drug manufacturer, compounder, distributor, or telehealth platform — has violated FDA regulations in a way that FDA considers significant enough to require a documented response.

What it is not:

• A shutdown order
• A recall notice
• Criminal charges
• An injunction

What it does:

• Formally notify the company of the specific violation
• Request a response within 15 business days explaining how the company will correct the problem
• Create a public record of the violation (all warning letters are posted on the FDA website)
• Put the company on notice that failure to remediate can escalate to more serious enforcement actions

The escalation options FDA holds if a company does not respond or correct: injunctions (court orders to halt specific operations), product seizures, consent decrees, or criminal referral for individuals involved in significant violations.

Most companies that receive warning letters do respond. Many continue operating while implementing corrections. The letter is the opening of a regulatory dialogue, not the end of one.

The two major GLP-1 warning waves

Wave 1: September 2025 — targeting compounders’ false generic claims

On September 9, 2025, FDA issued more than 50 warning letters to US and international companies compounding or manufacturing semaglutide and tirzepatide products.

The central violation in this wave: false claims that compounded products are “generic” equivalents of FDA-approved drugs.

Specifically, FDA cited companies for claiming their products contained “the same active ingredient” as Wegovy, Ozempic, or Zepbound and were equivalent in safety and efficacy. FDA’s position is that these claims are false and misleading because:

1. Compounded drugs do not go through the FDA approval process that establishes safety, efficacy, and manufacturing standards
2. Calling them “generic” implies regulatory equivalence that does not exist
3. Semaglutide and tirzepatide shortage designations that had justified compounding under 503B had already expired — the September 2025 wave accompanied the full enforcement transition to §503A-only compounding

The companies that received letters included telehealth platforms, independent pharmacies, and overseas manufacturers selling products into the US market. The letters did not generally allege product safety issues — they targeted the marketing language.

Wave 2: March 2026 — targeting telehealth marketing claims and private labelling

On March 3, 2026, FDA publicly released a second batch of 30 warning letters directed specifically at telehealth companies and online wellness clinics.

Two violations dominated this wave:

1. False equivalence claims. Companies were telling patients their compounded products were “effectively the same as” or “identical to” FDA-approved GLP-1 drugs. FDA treats this as consumer fraud as much as regulatory violation — patients making decisions about a $1,000+/month medication deserve accurate information about what they are buying.

2. Private-label obscuration. Many telehealth companies sell compounded GLP-1 products under their own brand name without disclosing which pharmacy actually compounded the product. Patients receiving “Brand X Semaglutide Injections” may have no idea whether their medication came from a licensed 503A pharmacy or an unregistered operation. FDA’s view: the actual compounder must be clearly identified on the product.

A recurring community concern about this dynamic: patients tracking their GLP-1 providers often say they have no idea who actually makes their medication — the telehealth platform brands everything under its own name, and the compounding partner is buried in terms and conditions if disclosed at all. This is exactly what FDA’s March 2026 wave addressed.

Why violation type matters: marketing vs safety

Not all warning letters are equally alarming from a patient perspective. Two distinct categories exist in the GLP-1 warning letter landscape:

Marketing and labelling violations (most of the September 2025 and March 2026 letters) concern the accuracy of claims made to patients. They do not necessarily indicate that the product itself is unsafe. A company can have misleading marketing and produce a properly-compounded, sterile product. These violations are remediable: change the claims, respond to FDA, continue operating.

Manufacturing or sterility violations (less common but more serious) concern the actual compounding process — contamination risks, unqualified staff performing sterile compounding, failure to follow standard procedures, inadequate quality controls. These letters raise direct product-safety concerns. The March 2025 Washington State pharmacy board action against Aequita Pharmacy — a Mochi Health compounding partner — which cited untrained staff performing sterile compounding, was this type of violation. For a plain-language guide to the terms used in these enforcement actions, see the compounding glossary.

When checking whether your provider has received a warning letter, identifying the violation type is the critical interpretive step. A marketing letter with an adequate remediation response is a different risk profile from a manufacturing letter with no documented correction.

How to check your provider

Our live FDA warning letters tracker at /regulatory/fda-warning-letters-glp1 covers the major GLP-1 warning letters, updated weekly. Each entry includes:

• The company named
• The date the letter was issued
• A summary of the core violation
• Whether a response has been documented
• Links to the original FDA document

For providers not yet in our tracker, you can search FDA’s full warning letters database directly at FDA.gov under Inspections, Compliance, Enforcement, and Criminal Investigations.

The compounding provider status tracker at /regulatory/compounding-tracker combines warning letter data with current operational status and legal actions for a more complete picture of each major provider.

What warning letters mean for the compounding market overall

The two waves are part of a coordinated enforcement shift that began when all 503A and 503B enforcement-discretion windows for GLP-1 compounding expired on May 22, 2025. For the full regulatory timeline that led to this point, see FDA compounding cliff.

Before May 2025, FDA had created a series of time-limited windows that effectively tolerated compounded GLP-1s while the shortage designations were in place. When those windows closed, FDA began enforcing more actively — and the warning-letter waves are the visible output of that shift.

The enforcement logic is consistent with FDA’s historical approach to compounding compliance cycles: first, public guidance; then warning letters to the most egregious violators; then escalating action against non-responders. The September 2025 and March 2026 waves are in the warning-letter stage. Companies that do not respond may face injunctions or seizure orders in 2026 and beyond.

For patients on compounded semaglutide, the practical implication has not changed from what was already true: the 503A vs 503B pathway is narrow, contested, and under active scrutiny. The warning letters are a signal that the regulatory environment is continuing to tighten, not reversing.

Warning letter data sourced from the FDA public website. This article is informational only and does not constitute legal advice. Related: Novo Nordisk Lawsuit Against Compounders · Compounding Provider Tracker · FDA Warning Letters Tracker · 503A vs 503B Explained